Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
22.92
+0.24 (+1.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
April 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
April 18, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Acquire AltheaDx
April 04, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
March 29, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
March 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
February 18, 2022
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
February 14, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 07, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
February 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
February 02, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
January 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
January 13, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
January 12, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
January 10, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
December 28, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Completes Acquisition of Cernostics
December 06, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
November 24, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
November 19, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies
November 17, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
November 15, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
November 10, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Third Quarter 2021 Results
November 08, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report
November 08, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
November 05, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
November 04, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
October 28, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting
October 26, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021
October 25, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
October 22, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.